Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sevoflurane, quantity: 250 ml - inhalation - excipient ingredients: - for induction and maintenance of general anaesthesia in adults and paediatric patients undergoing surgery.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - bortezomib baxter, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,bortezomib baxter, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,bortezomib baxter is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.,bortezomib baxter in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Hellas - gresk - Εθνικός Οργανισμός Φαρμάκων

baxter holding b.v., the netherlands kobaltweg 49, 3542ce utrecht - propofol - inj.em.in (ΓΑΛΑΚΤΩΜΑ ΓΙΑ ΕΓΧΥΣΗ Η ΕΝΕΣΗ) - 10mg/ml - propofol 10mg - propofol

Estland - estisk - Ravimiamet

baxter healthcare limited - elektrolüüdid - infusioonilahus - 250ml 30tk; 500ml 1tk; 1000ml 10tk; 250ml 1tk; 1000ml 1tk

Estland - estisk - Ravimiamet

baxter healthcare limited - süsivesikud - infusioonilahus - 5% 250ml 30tk; 5% 100ml 1tk; 5% 100ml 50tk; 5% 500ml 20tk; 5% 1000ml 10tk; 5% 50ml 1tk

Estland - estisk - Ravimiamet

baxter healthcare limited - naatriumkloriid - infusioonilahus - 0,9% 50ml 50tk; 0,9% 1000ml 10tk; 0,9% 50ml 1tk; 0,9% 100ml 1tk; 0,9% 250ml 1tk; 0,9% 500ml 1tk

Estland - estisk - Ravimiamet

baxter healthcare limited - süsivesikud - infusioonilahus - 100mg 1ml 250ml 30tk; 100mg 1ml 250ml 1tk; 100mg 1ml 1000ml 10tk; 100mg 1ml 500ml 1tk; 100mg 1ml 500ml 20tk; 100mg 1ml 1000ml 1tk; 100mg 1ml 250ml 36tk

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - ketamine hydrochloride 115.34 mg/ml equivalent to ketamine 100 mg/ml - solution for injection - 100 mg/ml - active: ketamine hydrochloride 115.34 mg/ml equivalent to ketamine 100 mg/ml excipient: nitrogen water for injection - ketamine-baxter is recommended: 1. as the sole anaesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation. ketamine-baxter is best suited for short procedures and it can be used with additional doses, for longer procedures; 2. for the induction of anaesthesia prior to the administration of other general anaesthetic agents; 3. to supplement low-potency agents, such as nitrous oxide.

Irland - engelsk - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - sevoflurane - inhalation vapour liquid - 100 per cent - sevoflurane

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - furosemide 10mg - solution for injection - 10 mg/ml - active: furosemide 10mg excipient: hydrochloric acid sodium hydroxide ph adjustment sodium chloride sodium hydroxide water for injection - furosemide-baxter injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. furosemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations.